title: Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
abstract: OBJECTIVE
  To estimate economic impact resulting from increased biologics use for treatment of rheumatoid arthritis (RA) and Crohn's disease (CD) in Argentina, Brazil, Colombia, and Mexico.
  
  
  METHODS
  The influence of increasing biologics use for treatment of RA during 2012-2022 and for treatment of CD during 2013-2023 was modeled from a societal perspective. The economic model incorporated current and projected medical, indirect, and drug costs and epidemiologic and economic factors. Costs associated with expanded biologics use for RA were compared with non-expanded use in Argentina, Brazil, Colombia, and Mexico. A similar analysis was conducted for CD in Brazil, Colombia, and Mexico.
  
  
  RESULTS
  Accounting for additional costs of biologics and medical and indirect cost offsets, the model predicts that expanded use of biologics for patients with RA from 2012 to 2022 will result in cumulative net cost savings of ARS$2.351 billion in Argentina, R$9.004 billion in Brazil, COP$728.577 billion in Colombia, and MXN$18.02 billion in Mexico; expanded use of biologics for patients with CD from 2013 to 2023 will result in cumulative net cost savings for patients with CD of R$0.082 billion in Brazil, COP$502.74 billion in Colombia, and MXN$1.80 billion in Mexico. Indirect cost offsets associated with expanded biologics use were a key driver in reducing annual per-patient net costs for RA and CD.
  
  
  CONCLUSIONS
  Future economic projections are limited by the potential variance between projected and actual future values of biologic prices, wages, medical costs, and gross national product for each country.
  
  
  CONCLUSIONS
  Increasing biologics use to treat RA and CD may limit cost growth over time by reducing medical and indirect costs. These findings may inform policy decisions regarding biologics use in Argentina, Brazil, Colombia, and Mexico.
authors.affiliation: a AbbVie Inc. , North Chicago , IL , USA.
authors.forename: Namita
authors.initials: N
authors.lastname: Tundia
authors.affiliation: b Catholic University of Paraná , Curitiba , Brazil.
authors.forename: Paulo Gustavo
authors.initials: PG
authors.lastname: Kotze
authors.affiliation: c National Autonomous University of Mexico , Mexico City , Mexico.
authors.forename: Jorge
authors.initials: J
authors.lastname: Rojas Serrano
authors.affiliation: d Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.
authors.forename: Mirhelen
authors.initials: M
authors.lastname: Mendes de Abreu
authors.affiliation: a AbbVie Inc. , North Chicago , IL , USA.
authors.forename: Martha
authors.initials: M
authors.lastname: Skup
authors.affiliation: e Analysis Group , New York , NY , USA.
authors.forename: Dendy
authors.initials: D
authors.lastname: Macaulay
authors.affiliation: e Analysis Group , New York , NY , USA.
authors.forename: James
authors.initials: J
authors.lastname: Signorovitch
authors.affiliation: a AbbVie Inc. , North Chicago , IL , USA.
authors.forename: Leonardo
authors.initials: L
authors.lastname: Chaves
authors.affiliation: a AbbVie Inc. , North Chicago , IL , USA.
authors.forename: Jingdong
authors.initials: J
authors.lastname: Chao
authors.affiliation: a AbbVie Inc. , North Chicago , IL , USA.
authors.forename: Yanjun
authors.initials: Y
authors.lastname: Bao
mesh_terms: D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000191:economics*; D001691:Biological Therapy / Q000191:economics* / Q000706:statistics & numerical data*; D003362:Cost-Benefit Analysis; D003424:Crohn Disease / Q000188:drug therapy*; D016527:Drug Costs; D017048:Health Care Costs / Q000639:trends*; D006801:Humans; D008800:Mexico; D013020:South America
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products
keywords: Argentina; Brazil; Colombia; Crohn’s disease; Mexico; Rheumatoid arthritis; economic assessment